U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07308938) titled 'Fluorometholone Study' on Dec. 26.
Brief Summary: The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone.
Study Start Date: March 31, 2026
Study Type: INTERVENTIONAL
Condition:
Keratitis Bacterial
Corneal Ulcer (Diagnosis)
Intervention:
DRUG: Adjunctive Topical Fluorometholone (FML) 0.1%
Adjunctive Topical Fluorometholone (FML) 0.1% will be used with the standard topical antibiotic therapy (Tobramycin [Tobrex] and/or Cefazolin [Ancef]).
OTHER:...